Payment overview · 2025
General Payments
$1,251.26
61 reported records · 22 companies
Healthcare provider profile · identity verified
Ralph Rodriguez, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NAPLES, FL · NPI 1891990685
Verified facts
What the public records show
CMS Open Payments records show Ralph Rodriguez, MD received $1,251.26 in general payments during 2025 across 61 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $306.76 | 24.5% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $252.07 | 20.1% | 13 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $90.62 | 7.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $55.63 | 4.5% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.39 | 4.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.08 | 3.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.13 | 3.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $38.53 | 3.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.97 | 2.9% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $35.84 | 2.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.48 | 2.7% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $32.28 | 2.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $31.08 | 2.5% | 2 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $27.03 | 2.2% | 1 | 2025 |
| MERZ NORTH AMERICA, INC. | Unresolved — no canonical attribution shown | $25.36 | 2.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $25.23 | 2.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.60 | 2.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.17 | 1.9% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $20.36 | 1.6% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.41 | 1.6% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $18.83 | 1.5% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $16.41 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,251.26 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $151.14 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $138.36 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $136.23 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $115.84 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $104.12 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $90.62 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $88.62 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $85.36 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $55.63 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $47.08 | 2 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $42.98 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $42.13 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $38.53 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $37.36 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $35.84 | 2 | 2025 |
Source payment records
|
|||||
| VIA MATRIX Normalized: via matrix |
Medical Supply | Organogenesis Inc. | $32.28 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $31.08 | 2 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | MERZ NORTH AMERICA, INC. | $25.36 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 82 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 41 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
62 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
82 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 299 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 268 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 229 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 206 | 64 |
| Atorvastatin Calcium | Atorvastatin Calcium | 189 | 67 |
| Losartan Potassium | Losartan Potassium | 172 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 163 | 59 |
| Gabapentin | Gabapentin | 152 | 80 |
| Lisinopril | Lisinopril | 144 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 43 |
| Methylprednisolone | Methylprednisolone | 130 | 94 |
| Simvastatin | Simvastatin | 130 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 41 |
| Trazodone Hcl | Trazodone Hcl | 104 | 41 |
| Diclofenac Sodium Er | Diclofenac Sodium | 101 | 55 |
| Furosemide | Furosemide | 96 | 38 |
| Clonazepam | Clonazepam | 94 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 40 |
| Eliquis | Apixaban | 82 | 20 |
| Diazepam | Diazepam | 80 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 80 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 33 |
| Prednisone | Prednisone | 76 | 29 |
| Ezetimibe | Ezetimibe | 71 | 22 |
| Metformin Hcl | Metformin Hcl | 68 | 26 |
| Omeprazole | Omeprazole | 67 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 21 |
| Azithromycin | Azithromycin | 64 | 52 |
| Ibuprofen | Ibuprofen | 62 | 28 |
| Mounjaro | Tirzepatide | 62 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 41 |
| Allopurinol | Allopurinol | 59 | 18 |
| Azelastine Hcl | Azelastine Hcl | 51 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 39 |
| Carvedilol | Carvedilol | 48 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 39 |
| Lorazepam | Lorazepam | 46 | suppressed |
| Pregabalin | Pregabalin | 46 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 13 |
| Ozempic | Semaglutide | 44 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 15 |
| Farxiga | Dapagliflozin Propanediol | 41 | 17 |
| Meloxicam | Meloxicam | 40 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 17 |
| Levofloxacin | Levofloxacin | 33 | 27 |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 15 |
| Potassium Chloride | Potassium Chloride | 30 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 30 | 11 |
| Spironolactone | Spironolactone | 29 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | 11 |
| Valacyclovir | Valacyclovir Hcl | 27 | 12 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 21 |
| Celecoxib | Celecoxib | 25 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 21 |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | 11 |
| Linzess | Linaclotide | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | 11 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Famotidine | Famotidine | 18 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 13 |
| Temazepam | Temazepam | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Glimepiride | Glimepiride | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,251.26 · 61 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, Extended Holter, FARXIGA, GIVLAARI, INSPIRE, JARDIANCE, JATENZO, Kerecis GraftGuide, Kerecis SurgiClose, Korlym, NURTEC ODT, QULIPTA, TEZSPIRE, TRELEGY ELLIPTA, UBRELVY, VIA MATRIX, VRAYLAR, XIFAXAN, Xeomin, ZAVZPRET, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error